News GSK abandons cough drug added in $2bn Bellus deal Three years after buying Bellus Health and its chronic cough candidate camlipixant for around $2 billion, GSK is abandoning the programme.
News FDA holds back MSD’s chronic cough drug again MSD will have to return to the drawing board to chart a course for US approval of its chronic cough treatment gefapixant.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.